Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250042 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00250042: Completed Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
NCT00250042 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00250042, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
Interventions
- DRUG Gleevec and Arsenic Trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00250042 record still lists
NCT00250042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Gleevec and Arsenic Trioxide is the first listed.
NCT00250042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00250042 about?
NCT00250042 is a clinical study titled "A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec". 1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
What is the current status of trial NCT00250042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2004-04. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00250042?
The interventions under investigation include: Gleevec and Arsenic Trioxide (DRUG).
Who is sponsoring clinical trial NCT00250042?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00250042's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia